CLINICAL TRIAL

RUSH2A - NCT03146078

Retinal RED

Observational

Early Phase 1

Rate of Progression in USH2A Related Retinal Degeneration

Rare Eye Disease concerned by the trial :
Retinitis Pigmentosa 39, Usher Syndrome

Status of the trial : active, not recruiting

Orphan drug recognition : N/A

Inclusion criteria : Participants with clinical diagnosis of rod-cone degeneration and at least 2 pathogenic or likely pathogenic mutations in USH2A gene; age ≥ 8 years

Exclusion criteria : Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A; Expected to enter experimental treatment trial at any time during this study; History of more than 1 year of cumulative treatment, at any time, with an agent 431 associated with pigmentary retinopathy.

Inclusion opening date : 01/08/2017

Inclusion closing date (previsional) : 31/12/2021

Children ☑

Adults ☑

Within ERN-EYE members

Locations of the trial :

Center for Ophthalmology, University of Tübingen
72076 Tübingen, Germany

Radboud University Medical Center,
Nijmegen, Netherlands

Ghent University, Ghent, Belgium

Institut de la Vision, Paris, France

Moorfields Eye Hospital NHS Foundation Trust,
London, United Kingdom



Funder type : Patient organization

More informations